Completed PHASE2 INTERVENTIONAL 6-arm NCT01738503

Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects

Open-Label, Multicenter, Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, Efficacy Markers, and Opioid Receptor Availability of Subcutaneous Injections of Depot Buprenorphine in Treatment Seeking Opioid-Dependent Subjects

Sponsor: Indivior Inc.

Conditions Opioid Related Disorder

Interventions RBP-6000 Subutex

Updated 7 times since 2017 Last updated: Jan 26, 2018 Started: Oct 31, 2012 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Opioid Related Disorder and is currently completed. Indivior Inc. leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2018 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Feb 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Indivior Inc.

Data source: Indivior Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Overland Park, United States